EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa

Hakim Ben Abdallah, Anne Bregnhøj, Thomas Emmanuel, Gautam Ghatnekar, Claus Johansen, Lars Iversen

JAMA Dermatology · 2024

DOI: 10.1001/jamadermatol.2023.4800 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Hakim Ben Abdallah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Heat-Shock Proteins, Hidradenitis Suppurativa. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Hidradenitis suppurativa is a painful immune-mediated disorder with limited treatment options; hence, a need exists for new treatments.

Objective

To evaluate the feasibility of heat shock protein 90 inhibition by RGRN-305 as a novel mechanism of action in treating moderate to severe hidradenitis suppurativa. Design, Setting, and Participants This was a parallel-design, double-blind, proof-of-concept, placebo-controlled randomized clinical trial conducted between September 22, 2021, and August 29, 2022, at the Department of Dermatology, Aarhus University Hospital in Denmark. The study included a 1- to 30-day screening period, a 16-week treatment period, and a 4-week follow-up period. Eligibility criteria included age 18 years or older and moderate to severe hidradenitis suppurativa with 6 or more inflammatory nodules or abscesses in at least 2 distinct anatomic regions. Of 19 patients screened, 15 patients were enrolled in the study. Intention-to-treat analysis was performed.

Interventions

Patients were randomly assigned (2:1) to receive oral RGRN-305, 250-mg tablet, or matching placebo once daily for 16 weeks. Main Outcomes and Measures The primary efficacy end point was the percentage of patients achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR-50) at week 16. Secondary efficacy end points included HiSCR-75 or HiSCR-90, Hidradenitis Suppurativa Physician’s Global Assessment, Dermatology Life Quality Index scores, and a pain numeric rating scale. Safety was assessed by adverse events, physical examinations, clinical laboratory measurements, and electrocardiograms.

Results

A total of 15 patients were enrolled, completed the study, and were included in all analyses (10 [67%] female; median age, 29 [IQR, 23-41] years). The primary end point HiSCR-50 at week 16 was achieved by a higher percentage in the RGRN-305 group (60% [6 of 10]) than in the placebo group (20% [1 of 5]). Improvements were also observed across all secondary end points at week 16, including higher rates of the harder-to-reach HiSCR levels; 50% (5 of 10) achieved HiSCR-75 and 30% (3 of 10) achieved HiSCR-90, whereas none of the placebo-treated patients achieved HiSCR-75 or HiSCR-90. RGRN-305 was well tolerated, with no deaths or serious adverse events, and treatment-emergent adverse events were similarly frequent between the RGRN-305 and placebo groups. Conclusions and Relevance The findings of this trial suggest that heat shock protein 90 inhibition by RGRN-305 offers a novel mechanism of action in treating hidradenitis suppurativa, warranting further evaluation in larger trials. Trial Registration ClinicalTrials.gov Identifier: NCT05286567

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heat-Shock ProteinsHidradenitis SuppurativaAdultFemaleHumansMaleDouble-Blind MethodSeverity of Illness IndexTreatment OutcomeYoung Adult

Substanzen

Heat-Shock Proteins

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark.
  • Regranion, Mount Pleasant, South Carolina.

Zitieren

APA

Ben Abdallah, H., Bregnhøj, A., Emmanuel, T., Ghatnekar, G., Johansen, C., & Iversen, L. (2024). Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2023.4800

Vancouver

Ben Abdallah H, Bregnhøj A, Emmanuel T, Ghatnekar G, Johansen C, Iversen L. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2023.4800

BibTeX
@article{BenAbdallah2024,
  author = {Ben Abdallah, Hakim and Bregnhøj, Anne and Emmanuel, Thomas and Ghatnekar, Gautam and Johansen, Claus and Iversen, Lars},
  title = {Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa},
  journal = {JAMA Dermatology},
  year = {2024},
  doi = {10.1001/jamadermatol.2023.4800}
}
Kostenlos starten →